Diane OK means return to French market, as EU OC safety review continues
This article was originally published in SRA
Now that the European Commission has confirmed that Bayer's acne product, Diane (cyproterone acetate plus ethinylestradiol), should remain on the market but under strict prescribing conditions1, attention will turn to the fate of combined hormonal contraceptives, which are also under scrutiny for their potential to cause thrombotic events.
You may also be interested in...
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.